Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year

被引：0
作者：
Andrew Blauvelt
Marjolein de Bruin-Weller
Eric L. Simpson
Zhen Chen
Marius Ardeleanu
Ana B. Rossi
机构：
[1] Oregon Medical Research Center,National Expertise Center of Atopic Dermatitis, Department of Dermatology and Allergology
[2] University Medical Center Utrecht,Department of Dermatology
[3] Oregon Health and Science University,undefined
[4] Regeneron Pharmaceuticals,undefined
[5] Inc.,undefined
[6] Sanofi Genzyme,undefined
来源：
Dermatology and Therapy | 2022年 / 12卷
关键词：
Atopic dermatitis; Dupilumab; Efficacy; Long-term; Outcome measures;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
[media not available: see fulltext]
引用
收藏
页码：9 / 13
页数：4
相关论文
共 26 条
  • [1] Weidinger S(2018)Atopic dermatitis Nat Rev Dis Primers 4 1-437
  • [2] Beck LA(2017)Commonality of the IL-4/IL-13 pathway in atopic diseases Expert Rev Clin Immunol 13 425-1204
  • [3] Bieber T(2020)Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation Allergy 75 1188-1101
  • [4] Kabashima K(2018)Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ) Br J Dermatol 178 1083-2303
  • [5] Irvine AD(2017)Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial Lancet 389 2287-2348
  • [6] Gandhi NA(2016)Two phase 3 trials of dupilumab versus placebo in atopic dermatitis N Engl J Med 375 2335-895
  • [7] Pirozzi G(2021)What are the best endpoints for eczema area and severity index and scoring atopic dermatitis in clinical practice? A prospective observational study Br J Dermatol 184 888-79
  • [8] Graham NMH(2016)Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative) Br J Dermatol 175 69-undefined
  • [9] Le Floc'h A(undefined)undefined undefined undefined undefined-undefined
  • [10] Allinne J(undefined)undefined undefined undefined undefined-undefined
123